by Higgenbotham » Mon Oct 19, 2026 10:48 am
Higgenbotham wrote: Mon Sep 28, 2026 11:26 am
That's sort of like saying education and health care are no longer utilities because we raised the price and made them 25 percent of GDP.
Top 10 hospitals in the U.S. by net patient revenue
Rank Hospital name City State Net patient revenue
1 NewYork-Presbyterian Weill Cornell Medical Center New York NY $10,091,059,200
2 Tisch Hospital New York NY $8,131,192,320 Explore
3 Stanford Hospital - 300 Pasteur Dr Palo Alto CA $7,893,382,656 Explore
4 Cleveland Clinic Main Campus Cleveland OH $7,426,526,720 Explore
5 AdventHealth Orlando (FKA Florida Hospital Orlando) Orlando FL $7,153,306,624
6 Vanderbilt University Medical Center Nashville TN $6,903,583,232
7 UCSF Helen Diller Medical Center San Francisco CA $6,828,788,224
8 University of Texas MD Anderson Cancer Center Houston TX $6,062,692,352
9 University Hospital Ann Arbor MI $5,572,471,808
10 Memorial Sloan Kettering Cancer Center New York NY $5,457,068,544
Let's pick on Stanford because I'm aware of the level of fraud, but it's probably endemic.
Stanford Health Care (SHC) is a tax-exempt non-profit organization whose purpose is to provide patient care services through its 21,000 employees at 3 hospitals and 60 clinics in the Palo Alta, California area. SHC consists of 21 tax-exempt non profit organizations, 43 related organizations taxed as a partnership, and 31 organizations taxed as a corporation or trust.
In 2024, SHC reported total revenue of $8 billion with the largest source of revenue reported to be patient revenue ($7.9 billion). Expenses were $7.5 billion (including $251 million in depreciation) with the largest expenses reported to be compensation ($3.3 billion), purchased services and fees for services ($1.9 billion), supplies ($1.2 billion), and office-related expenses ($384 million).
Net assets are $7.5 billion at year-end 2024 (compared to $6.5 billion the prior year).
21,893 employees received $3.3 billion in compensation, which equates to an average of $151,000. 9,927 employees received more than $100,000 with 20 of the most highly compensated reported to be:
$6,014,254: David Entwistle, President and CEO
$3,172,743: Lloyd Minor, Director*
$2,995,552: Quinn McKenna, COO
$2,543,596: Paul King, Director*
$2,526,363: Linda Hoff, CFO
$2,052,677: Priya Singh, VP and Chief Strategy Officer *
$1,821,989: Randall Livingston, Director*
$1,397,889: Sridhar Seshadri, Chief Cancer Operating Officer
$1,368,268: Eila Skinner, Director*
$1,210,323: Alison Kerr, VP Service Lines and CAO
$1,121,657: Dale Beatty, Chief Nurse Executive
$1,072,860: Thomas Montine, Director*
$ 977,492: Thomas Kim, V,Chief Marketing Development Officer
$ 946,361: Carol Rorig, VP and Chief HR Officer
$ 891,092: James Martin, VP, Controller
$ 834,765: Helen Wilmot, SVP Chief Facilities General Services and Planning
$ 779,163: Gary Fritz, VP – Applications
$ 718,540: Timothy Seay-Morrison, VP Chief Ambu Svc Lin Officer
$ 649,876: Jay Shah, Director*
$ 490,902: Elizabeth Oyekan, VP Pharmacy and Imaging Services
The 20 highly compensated employees listed above received $35 million in compensation in 2024.
Bezos may argue that they make really good burgers.
To read about the supplemental executive retirement plan and housing allowances, go to the Form 990, Schedule J, Part III, Supplemental Information.
SHC has made housing loans to employees (it is unclear why a tax-exempt non-profit health care company is making housing loans – including reduced interest rate and zero interest rate loans – to employees since the purpose of non-profit healthcare companies is not to provide housing loans, especially for multimillion dollar homes):
David Entwistle received 2 loans (for housing) totaling $2 million. The balance due is $2 million.
Dale Beatty received 1 loan (for housing) for $500,000. The balance due is $500,000.
Linda Hoff received 1 loan (for housing) for $953,000. The balance due is $703,000.
Gary Fritz, a former employee received 1 loan (for housing) for $300,000. The balance due is $300,000.
To read the IRS Form 990 (2024), click here.
https://paddockpost.com/2026/06/28/exec ... care-2024/
And maybe if they open a second burger joint and a third they should double or triple their compensation and get more free million dollar houses. And God knows what else.
How much money has been spent on Alzheimer's research in the past 30 years and, with all the money spent, has even one person been cured of Alzheimer's?
AI Overview
The direct answers to your questions are straightforward: Tens of billions of dollars have been spent globally on Alzheimer's research over the past 30 years, but to date, not a single person has been cured of the disease.
1. How Much Money Has Been Spent?
While a precise global figure encompassing every private pharmaceutical company, university, and government worldwide over 30 years is difficult to aggregate into one number, the total is securely in the tens of billions of dollars.
The vast majority of this funding has been back-loaded into the last decade. To give you a sense of scale using the U.S. National Institutes of Health (NIH)—the world's largest public funder of health research—the trajectory looks like this:
The 1990s and 2000s: Federal funding for Alzheimer’s hovered at low levels, generally under $500 million annually.
Alzheimer's Impact Movement
The Turning Point (2011): The passage of the National Alzheimer's Project Act (NAPA) sparked a massive legislative push to treat dementia as a public health priority.
Current Day: Annual NIH funding for Alzheimer's and related dementias has quadrupled over the last decade, reaching approximately $3.9 billion per year.
When you add up decades of escalating NIH budgets, billions spent by non-profits like the Alzheimer's Association, and the immense R&D budgets of private pharmaceutical giants, the cumulative total easily crosses tens of billions.
2. Has Anyone Been Cured?
No. There are currently zero survivors of Alzheimer's disease. Once a person develops the late-stage cognitive decline associated with Alzheimer's, the damage to the brain's neurons is considered permanent and irreversible by modern medical standards.
Where is the Money Going if There is No Cure?
It is natural to look at billions of dollars and wonder why it hasn't bought a cure. Scientists point to a few reasons for this bottleneck:
We Misunderstood the Disease for Decades: For a long time, the dominant theory was that clearing out "amyloid plaques" (abnormal protein buildups in the brain) would cure the disease. Billions were spent developing drugs to clear these plaques. While new drugs like lecanemab and donanemab finally succeeded in clearing them and slowing down early-stage cognitive decline, they did not reverse the damage or stop the disease entirely. This revealed that plaques are likely a symptom, not the root cause.
The Shift to Prevention: Because fixing a deeply damaged brain is so difficult, much of today’s funding is pivoting toward prevention and early detection. Breakthroughs like newly developed blood tests can now spot the chemical signs of Alzheimer's years before symptoms appear, allowing doctors to intervene before irreversible damage occurs.
Exploring New Theories: Funding is finally diversifying away from just looking at plaques. Current trials are exploring completely different angles, such as repairing brain metabolism (how the brain uses energy), stopping "tau tangles" (another destructive protein), and reducing brain inflammation.
It doesn't matter to them how wrong they are as long as the grant money keeps flowing.
It's the Fauci Industrial Complex.
[quote=Higgenbotham post_id=95496 time=1790609216 user_id=100]
That's sort of like saying education and health care are no longer utilities because we raised the price and made them 25 percent of GDP.[/quote]
[quote]Top 10 hospitals in the U.S. by net patient revenue
Rank Hospital name City State Net patient revenue
1 NewYork-Presbyterian Weill Cornell Medical Center New York NY $10,091,059,200
2 Tisch Hospital New York NY $8,131,192,320 Explore
3 Stanford Hospital - 300 Pasteur Dr Palo Alto CA $7,893,382,656 Explore
4 Cleveland Clinic Main Campus Cleveland OH $7,426,526,720 Explore
5 AdventHealth Orlando (FKA Florida Hospital Orlando) Orlando FL $7,153,306,624
6 Vanderbilt University Medical Center Nashville TN $6,903,583,232
7 UCSF Helen Diller Medical Center San Francisco CA $6,828,788,224
8 University of Texas MD Anderson Cancer Center Houston TX $6,062,692,352
9 University Hospital Ann Arbor MI $5,572,471,808
10 Memorial Sloan Kettering Cancer Center New York NY $5,457,068,544[/quote]
Let's pick on Stanford because I'm aware of the level of fraud, but it's probably endemic.
[quote]Stanford Health Care (SHC) is a tax-exempt non-profit organization whose purpose is to provide patient care services through its 21,000 employees at 3 hospitals and 60 clinics in the Palo Alta, California area. SHC consists of 21 tax-exempt non profit organizations, 43 related organizations taxed as a partnership, and 31 organizations taxed as a corporation or trust.
In 2024, SHC reported total revenue of $8 billion with the largest source of revenue reported to be patient revenue ($7.9 billion). Expenses were $7.5 billion (including $251 million in depreciation) with the largest expenses reported to be compensation ($3.3 billion), purchased services and fees for services ($1.9 billion), supplies ($1.2 billion), and office-related expenses ($384 million).
Net assets are $7.5 billion at year-end 2024 (compared to $6.5 billion the prior year).
21,893 employees received $3.3 billion in compensation, which equates to an average of $151,000. 9,927 employees received more than $100,000 with 20 of the most highly compensated reported to be:
$6,014,254: David Entwistle, President and CEO
$3,172,743: Lloyd Minor, Director*
$2,995,552: Quinn McKenna, COO
$2,543,596: Paul King, Director*
$2,526,363: Linda Hoff, CFO
$2,052,677: Priya Singh, VP and Chief Strategy Officer *
$1,821,989: Randall Livingston, Director*
$1,397,889: Sridhar Seshadri, Chief Cancer Operating Officer
$1,368,268: Eila Skinner, Director*
$1,210,323: Alison Kerr, VP Service Lines and CAO
$1,121,657: Dale Beatty, Chief Nurse Executive
$1,072,860: Thomas Montine, Director*
$ 977,492: Thomas Kim, V,Chief Marketing Development Officer
$ 946,361: Carol Rorig, VP and Chief HR Officer
$ 891,092: James Martin, VP, Controller
$ 834,765: Helen Wilmot, SVP Chief Facilities General Services and Planning
$ 779,163: Gary Fritz, VP – Applications
$ 718,540: Timothy Seay-Morrison, VP Chief Ambu Svc Lin Officer
$ 649,876: Jay Shah, Director*
$ 490,902: Elizabeth Oyekan, VP Pharmacy and Imaging Services
The 20 highly compensated employees listed above received $35 million in compensation in 2024.[/quote]
Bezos may argue that they make really good burgers.
[quote]To read about the supplemental executive retirement plan and housing allowances, go to the Form 990, Schedule J, Part III, Supplemental Information.
SHC has made housing loans to employees (it is unclear why a tax-exempt non-profit health care company is making housing loans – including reduced interest rate and zero interest rate loans – to employees since the purpose of non-profit healthcare companies is not to provide housing loans, especially for multimillion dollar homes):
David Entwistle received 2 loans (for housing) totaling $2 million. The balance due is $2 million.
Dale Beatty received 1 loan (for housing) for $500,000. The balance due is $500,000.
Linda Hoff received 1 loan (for housing) for $953,000. The balance due is $703,000.
Gary Fritz, a former employee received 1 loan (for housing) for $300,000. The balance due is $300,000.
To read the IRS Form 990 (2024), click here.[/quote]
https://paddockpost.com/2026/06/28/executive-compensation-at-stanford-health-care-2024/
And maybe if they open a second burger joint and a third they should double or triple their compensation and get more free million dollar houses. And God knows what else.
[quote]
How much money has been spent on Alzheimer's research in the past 30 years and, with all the money spent, has even one person been cured of Alzheimer's?
AI Overview
The direct answers to your questions are straightforward: Tens of billions of dollars have been spent globally on Alzheimer's research over the past 30 years, but to date, not a single person has been cured of the disease.
1. How Much Money Has Been Spent?
While a precise global figure encompassing every private pharmaceutical company, university, and government worldwide over 30 years is difficult to aggregate into one number, the total is securely in the tens of billions of dollars.
The vast majority of this funding has been back-loaded into the last decade. To give you a sense of scale using the U.S. National Institutes of Health (NIH)—the world's largest public funder of health research—the trajectory looks like this:
The 1990s and 2000s: Federal funding for Alzheimer’s hovered at low levels, generally under $500 million annually.
Alzheimer's Impact Movement
The Turning Point (2011): The passage of the National Alzheimer's Project Act (NAPA) sparked a massive legislative push to treat dementia as a public health priority.
Current Day: Annual NIH funding for Alzheimer's and related dementias has quadrupled over the last decade, reaching approximately $3.9 billion per year.
When you add up decades of escalating NIH budgets, billions spent by non-profits like the Alzheimer's Association, and the immense R&D budgets of private pharmaceutical giants, the cumulative total easily crosses tens of billions.
2. Has Anyone Been Cured?
No. There are currently zero survivors of Alzheimer's disease. Once a person develops the late-stage cognitive decline associated with Alzheimer's, the damage to the brain's neurons is considered permanent and irreversible by modern medical standards.
Where is the Money Going if There is No Cure?
It is natural to look at billions of dollars and wonder why it hasn't bought a cure. Scientists point to a few reasons for this bottleneck:
We Misunderstood the Disease for Decades: For a long time, the dominant theory was that clearing out "amyloid plaques" (abnormal protein buildups in the brain) would cure the disease. Billions were spent developing drugs to clear these plaques. While new drugs like lecanemab and donanemab finally succeeded in clearing them and slowing down early-stage cognitive decline, they did not reverse the damage or stop the disease entirely. This revealed that plaques are likely a symptom, not the root cause.
The Shift to Prevention: Because fixing a deeply damaged brain is so difficult, much of today’s funding is pivoting toward prevention and early detection. Breakthroughs like newly developed blood tests can now spot the chemical signs of Alzheimer's years before symptoms appear, allowing doctors to intervene before irreversible damage occurs.
Exploring New Theories: Funding is finally diversifying away from just looking at plaques. Current trials are exploring completely different angles, such as repairing brain metabolism (how the brain uses energy), stopping "tau tangles" (another destructive protein), and reducing brain inflammation.[/quote]
It doesn't matter to them how wrong they are as long as the grant money keeps flowing.
It's the Fauci Industrial Complex.